<scp>SFRP</scp>5 correlates with obesity and metabolic syndrome and increases after weight loss in children

Tan, Xinrui; Wang, Xiaoli; Chu, Haiping; Liu, Honghong; Yi, Xiaoqing; Xiao, Yanfeng

doi:10.1111/cen.12361

Cited by 36 publications

(33 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 However, our study did not find any association between the SFRP5 level and variables of obesity. Our result was in consistency with the observation of Schulte, 17 whose study found that circulating SFRP5 concentration was not influenced by obesity.…”

Section: Discussioncontrasting

confidence: 84%

Secreted Frizzled-Related Protein 5 (SFRP5) in Patients with Obstructive Sleep Apnea

Zhang

Huang

Xiao

et al. 2017

Chinese Medical Sciences Journal

View full text Add to dashboard Cite

Key words: secreted frizzled-related protein 5 (SFRP5); obstructive sleep apnea (OSA); obesity Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5 and sleeping characteristics as well as biochemical parameters of OSA patients.Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea-hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m 2 . All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive Creactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison.Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDLcholesterol level (r=−0.472 and P=0.003; r=−0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment.Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However, no correlation was observed between SFRP5 and FBG or sleep parameters. The SFRP5 level of OSA patients did not differ from that of non-OSA individuals in our study.

show abstract

Section: Discussioncontrasting

confidence: 84%

Secreted Frizzled-Related Protein 5 (SFRP5) in Patients with Obstructive Sleep Apnea

Zhang

Huang

Xiao

et al. 2017

Chinese Medical Sciences Journal

View full text Add to dashboard Cite

show abstract

“…They found that circulating SFRP5 was associated inversely with hsCRP, leptin, IL-6, TNFα and IL-1β and positively with adiponectin [12, 13, 15, 36, 37]. On the cellular level, the treatment with recombinant SFRP5 reduced the release of IL-6 by 49% in vitro in TNFα-induced primary human adipocytes.…”

Section: Discussionmentioning

confidence: 99%

Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study

Carstensen‐Kirberg

Kannenberg

Huth

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

AimsSecreted frizzled-related protein (Sfrp)5 has beneficial effects on insulin sensitivity, inflammation and cardiovascular risk in different mouse models, but its relevance for cardiometabolic diseases in humans is controversial. We aimed to characterise associations of circulating SFRP5 with cardiometabolic risk factors and prediabetes/type 2 diabetes in a large population-based cohort.MethodsCross-sectional associations between serum SFRP5 and cardiometabolic risk factors as well as prediabetes/type 2 diabetes were investigated in 1096 participants aged 62–81 years from the German KORA F4 study, of whom 666 had prediabetes or type 2 diabetes. Multivariable linear regression models were adjusted for potential confounders including age, sex, body mass index (BMI), lifestyle factors, lipids, hypertension, kidney function and myocardial infarction.ResultsHigher serum SFRP5 levels were associated with lower HbA1c, BMI, systolic blood pressure, estimated glomerular filtration rate and high-sensitivity C-reactive protein levels and with higher levels of high-density lipoprotein cholesterol and adiponectin in the fully adjusted model (all P < 0.009). In contrast, favourable associations between SFRP5 and glycaemia, insulin, insulin resistance and other cardiometabolic risk factors were attenuated after adjustment for BMI. Serum SFRP5 levels were lower in participants with prediabetes or type 2 diabetes [(median (25th; 75th percentile) 48.8 (35.5; 65.7) ng/ml] compared to participants with normal glucose tolerance [55.9 (42.6; 69.6) ng/ml] (P < 0.001). In the fully adjusted model, higher SFRP5 was associated with lower odds of prediabetes/type 2 diabetes [OR (95% CI) (0.72 (0.58; 0.89)) per doubling of SFRP5, P < 0.01].ConclusionsHigher serum SFRP5 was inversely associated with multiple risk factors for type 2 diabetes and cardiovascular diseases. However, BMI represents a strong confounder of some of these associations. Higher circulating SFRP5 was also associated with lower odds of prediabetes/type 2 diabetes, and this association was independent of BMI. Thus, SFRP5 emerges as novel biomarker that merits further research in the context of prevention of cardiometabolic diseases.Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-017-0591-x) contains supplementary material, which is available to authorized users.

show abstract

“…Although some conflicting data have been reported regarding the magnitude of Sfrp5 secretion by human WAT 346, 347 , an increasing body of evidence suggests that Sfrp5 is dynamically regulated in humans. Several studies have shown that circulating levels of Sfrp5 are reduced in obese individuals, particularly in those exhibiting clear evidence of metabolic dysfunction, such as impaired glucose tolerance and insulin resistance 346, 348–350 . Consistently, human Sfrp5 transcript levels in visceral adipose tissue decrease with obesity 351 .…”

Section: Cardiovascular Actions Of Select Adipokinesmentioning

confidence: 99%

Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease

Fuster

Ouchi

Gokce

et al. 2016

Circulation Research

517

391

View full text Add to dashboard Cite

Obesity is causally linked with the development of cardiovascular disorders. Accumulating evidence indicates that cardiovascular disease is the “collateral damage” of obesity-driven adipose tissue dysfunction that promotes a chronic inflammatory state within the organism. Adipose tissues secrete bioactive substances, referred to as adipokines, which largely function as modulators of inflammation. The microenvironment of adipose tissue will affect the adipokine secretome, having actions on remote tissues. Obesity typically leads to the upregulation of pro-inflammatory adipokines and the downregulation of anti-inflammatory adipokines, thereby contributing to the pathogenesis of cardiovascular diseases. In this review, we focus on the microenvironment of adipose tissue and how it influences cardiovascular disorders, including atherosclerosis and ischemic heart diseases, through the systemic actions of adipokines.

show abstract

SFRP5 correlates with obesity and metabolic syndrome and increases after weight loss in children

Abstract: Serum SFRP5 is regulated by weight status and seems to be correlated with metabolic disorders in children.

Cited by 36 publications

References 27 publications

Secreted Frizzled-Related Protein 5 (SFRP5) in Patients with Obstructive Sleep Apnea

Secreted Frizzled-Related Protein 5 (SFRP5) in Patients with Obstructive Sleep Apnea

Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study

Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease

Contact Info

Product

Resources

About